The Zhitong Finance App learned that from being approved for marketing to actually generating commercial value, innovative drugs often have to cross multiple thresholds such as hospital access, doctor prescriptions, channel coverage, and patient use. The national Class 1 innovative drug Pidacan®, independently developed by Peger Biotech (02565.HK), is completing this critical leap forward.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.